Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PRS-060 in Healthy Subjects
NCT03384290Phase 1Completed
- Sponsor
- Pieris Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in asthma comparing PRS-060 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events (AEs) at 30 days, Change in blood pressure at 30 days and 10 more. Started Dec 2017; status: completed.
02
Drugs
elarekibep
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03384290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384290.